Back to Crohns Disease And Colitis
NCT05068284
NCT05068284
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with Crohn's Disease for at least 3 months before the study starts.
- Your Crohn's Disease activity falls within a certain range of severity, based on a standard scoring system called the CDAI (with a score between 220 and 450), meaning your disease is moderately to severely active.
- A camera examination of your gut (endoscopy) has shown active inflammation in your intestines, reaching a specific minimum score depending on which part of your gut is affected (confirm with trial site for exact score details).
- You have either not responded well enough to, or could not tolerate, at least one of the following medications: infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, ustekinumab, or risankizumab.
Who may not be able to join:
- You have previously had a bad reaction to or could not tolerate the medication adalimumab.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Terminated
Phase
Phase 2
Sponsor
AbbVie
Registry
clinicaltrials_gov
Start date
31 January 2022
Est. completion
20 July 2023
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇿 Czechia
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
🇵🇹 Portugal
Puerto Rico
🇸🇰 Slovakia
🇰🇷 South Korea
🇪🇸 Spain
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.